Navigation Links
Perrigo Company to Present at the Leerink Swann 2012 Global Healthcare Conference
Date:2/8/2012

ALLEGAN, Mich., Feb. 8, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15th, at 2:30 PM (EST) at the Waldorf Astoria in New York.  

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 


'/>"/>
SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017 ... Market Outlook to 2022", provides key market data on ... value, in millions of US dollars, volume (in units) ... Energy X-Ray Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). ... data for each of these market segements, and global ...
(Date:1/16/2017)... , Jan. 16, 2017 Infusion ... devices used for administering medications in a controlled, ... used for therapeutic purposes in critical care, pain ... required to make patient,s feel comfortable and pain ... errors which would lead to serious life threatening ...
(Date:1/16/2017)... BOTHELL, Wash. , Jan. 16, 2017  Verathon ® ... devices, announced the launch of new GlideScope ® Spectrum TM ... all-new Dynamic Light Control TM and Ambient Light Reduction TM ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the following ... This year’s influenza shot seems to be having no effect on keeping this ... least half of the people around are coughing, sneezing, or sniffling , ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... in the Aesthetic Surgery Journal , the official journal of The American ... on lower eyelid retraction surgery. The procedure is designed to correct drooping, retracted ...
(Date:1/16/2017)... CITY, UT (PRWEB) , ... January 16, 2017 , ... ... disease not only to treat, but to test for, as well. The money spent ... billion every year.(1) Doctors in the U.S. screen patients for cancer more than in ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar Medical, ... of the medical device company, effective immediately. , “This is perfect timing for ... a strong track record in medical device market development and revenue growth, particularly ...
(Date:1/15/2017)... ... 15, 2017 , ... In this role, Courtney will be responsible for developing ... & allergy friendly mark. This certification program was created by ASL and the nonprofit ... be more suitable for the 60+ million people living in the U.S. with asthma ...
Breaking Medicine News(10 mins):